profit from every $100 of sales.
$0$100
Sight Sciences
$10.83-1.46% today
+53.6% in 1 year
1-year low $3.451-year high $11.01
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Sight Sciences sold, what it kept, and what it did with the cash.
Sales went from $71.3 million in 2022 to $77.4 million in 2025, with -$38.4 million of profit last year.
SalesProfit
Sight Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Sight Sciences | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Sight Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 71 | 81 | 80 | 77 | |
| 59 | 69 | 68 | 67 | |
| -84 | -57 | -51 | -37 | |
| -81 | -49 | -46 | -33 | |
| -86 | -56 | -52 | -38 | |
| -1.80 | -1.14 | -1.03 | -0.74 | |
| 82.7% | 85.3% | 85.5% | 86.2% | |
| -117.7% | -70.7% | -63.3% | -48.0% | |
| -120.9% | -68.5% | -64.5% | -49.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 213 | 167 | 143 | 115 |
| Cash | 185 | 138 | 120 | 92 |
| Total debt | 35 | 35 | 40 | 41 |
| Total liabilities | 53 | 46 | 55 | 51 |
| 160 | 120 | 88 | 64 | |
| 48 | 49 | 50 | 52 | |
| -33.1% | -25.4% | -28.8% | -25.1% | |
| -53.9% | -46.2% | -58.8% | -60.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -76 | -47 | -22 | -30 | |
| 1 | 1 | 0 | 0 | |
| -77 | -48 | -23 | -30 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 13 | 15 | 17 | 13 |
Valuation
- –
- –
- –
- 4.7×
- 7.8×
- –
- –
- -5.0%
- -6.4%
- 0.0%
Profitability
- 86.2%
- -48.0%
- -49.7%
- -40.9%
- -37.2%
- -36.1%
- -59.1%
- -34.0%
- -38.9%
- 16.0%
Growth
- +2.7%
- –
- −31.6%
- –
- +2.4%
Financial health
- -1.6×
- 0.76
- 37.3%
- -13.7×
- 5.86
- 5.48
- 0.73
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 963
Bottom 6%of 894
Bottom 23%of 908
Bottom 16%of 991
What analysts expect
- Average price target
- $9.67
- Range
- $8.00 – $12.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.16 | -0.19 | +15.8% |
| Mar 4, 2026 | -0.08 | -0.15 | +46.7% |
| Nov 6, 2025 | -0.16 | -0.26 | +38.5% |
| Aug 7, 2025 | -0.23 | -0.25 | +8.0% |
| May 8, 2025 | -0.28 | -0.29 | +3.4% |
| Mar 5, 2025 | -0.23 | -0.22 | −4.5% |
| Nov 7, 2024 | -0.22 | -0.23 | +4.3% |
| Aug 1, 2024 | -0.25 | -0.31 | +19.4% |
News
Amazon Plans to Spend More on AI. Here’s Why the Stock is a Once-in-a-Decade Buy Hiding in Plain Sight.Yahoo Finance · Oct 31, 2026Microsoft Has a $1 Trillion Opportunity Hiding in Plain SightYahoo Finance · Oct 23, 2026Hedge fund manager sees a bull market hiding in plain sightYahoo Finance · Oct 18, 2026Was The Run In Super Micro Stock Hiding In Plain Sight?Yahoo Finance · Oct 17, 2026Trump's former defense secretary sees no end in sight for Iran war — to the benefit of America's 'greatest adversary'CNBC · Oct 8, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
37No pass
Philip Fisher
40No pass
Peter Lynch
28No pass
Joel Greenblatt
2No pass
Charlie Munger
36No pass
Terry Smith
37No pass
Questions about Sight Sciences
Is Sight Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sight Sciences AI analysis
What does Sight Sciences do?
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It is in Medical - Devices.
Does Sight Sciences pay a dividend?
No. Sight Sciences does not pay a dividend at the moment.
Is Sight Sciences stock halal?
Yes. Sight Sciences passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has Sight Sciences stock done over the past year?
Up 53.6% over the past twelve months, to $10.83. It traded between $3.45 and $11.01, close to its high.
Who are Sight Sciences's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Sight Sciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.